ANGLE Reels In First Patient For Major US FDA Clinical Study

05 Apr 2018

• By Catherine Longworth

ANGLE is moving closer to its goal of becoming the first ever company to receive US FDA clearance for a device that can harvest intact circulating tumor cells (CTCs) from patient blood for subsequent analysis.

British diagnostics firm ANGLE is edging closer to its goal to become the first ever company to get US FDA clearance to market a circulating tumor cell-harvesting system for downstream analysis and clinical diagnosis.

The company has enrolled the first patient into its ANG-002 FDA clinical study for metastatic breast cancer. The study involves...